{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:31:18Z","timestamp":1767141078458,"version":"build-2238731810"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"17-18","license":[{"start":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T00:00:00Z","timestamp":1532390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00508-018-1365-5","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T07:31:08Z","timestamp":1532417468000},"page":"495-504","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ruxolitinib therapy for myelofibrosis in Austria"],"prefix":"10.1007","volume":"130","author":[{"given":"Maria-Theresa","family":"Krauth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Burgstaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Buxhofer-Ausch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnther","family":"Gastl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Keil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Krippl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Melchardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Petzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Rumpold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thamer","family":"Sliwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"W\u00f6hrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"W\u00f6lfler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Gisslinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,24]]},"reference":[{"issue":"4","key":"1365_CR1","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/ejh.12256","volume":"92","author":"O Moulard","year":"2014","unstructured":"Moulard O, Mehta J, Fryzek J, et\u00a0al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92(4):289\u201397.","journal-title":"Eur J Haematol"},{"key":"1365_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev.med.60.041707.160528","volume":"60","author":"OI Abdel-Wahab","year":"2009","unstructured":"Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med. 2009;60:233\u201345.","journal-title":"Annu Rev Med"},{"issue":"13","key":"1365_CR3","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, et\u00a0al. New prognostic scoring system for primary myelofibrosis based on a\u00a0study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895\u2013901.","journal-title":"Blood"},{"issue":"9","key":"1365_CR4","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a\u00a0study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703\u20138.","journal-title":"Blood"},{"issue":"2","key":"1365_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s12185-010-0530-z","volume":"91","author":"F Delhommeau","year":"2010","unstructured":"Delhommeau F, Jeziorowska D, Marzac C, Casadevall N. Molecular aspects of myeloproliferative neoplasms. Int J Hematol. 2010;91(2):165\u201373.","journal-title":"Int J Hematol"},{"key":"1365_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1756-8722-6-79","volume":"6","author":"RA Mesa","year":"2013","unstructured":"Mesa RA, Cortes J. Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing. J\u00a0Hematol Oncol. 2013;6:79.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"1365_CR7","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2012-05-399048","volume":"120","author":"V Gupta","year":"2012","unstructured":"Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood. 2012;120(7):1367\u201379.","journal-title":"Blood"},{"issue":"4","key":"1365_CR8","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/bjh.12274","volume":"161","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a\u00a0placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol. 2013;161(4):508\u201316.","journal-title":"Br J Haematol"},{"issue":"5","key":"1365_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, et\u00a0al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N\u00a0Engl J Med. 2015;372(5):426\u201335.","journal-title":"N Engl J Med"},{"issue":"9\u201310","key":"1365_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00508-016-1120-8","volume":"129","author":"T Sliwa","year":"2017","unstructured":"Sliwa T, Beham-Schmid C, Burgstaller S, et al. Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement. Wien Klin Wochenschr. 2017;129(9\u201310):293\u2013302.","journal-title":"Wien Klin Wochenschr"},{"issue":"9","key":"1365_CR11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N\u00a0Engl J Med. 2012;366(9):799\u2013807.","journal-title":"N Engl J Med"},{"issue":"9","key":"1365_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N\u00a0Engl J Med. 2012;366(9):787\u201398.","journal-title":"N Engl J Med"},{"issue":"4","key":"1365_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3324\/haematol.2014.115840","volume":"100","author":"S Verstovsek","year":"2015","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a\u00a0median 3\u2011year follow-up of COMFORT-I. Haematologica. 2015;100(4):479\u201388.","journal-title":"Haematologica"},{"issue":"25","key":"1365_CR14","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","volume":"122","author":"F Cervantes","year":"2013","unstructured":"Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a\u00a0phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047\u201353.","journal-title":"Blood"},{"issue":"8","key":"1365_CR15","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a\u00a0phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30(8):1701\u20137.","journal-title":"Leukemia"},{"issue":"1","key":"1365_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5\u2011year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J\u00a0Hematol Oncol. 2017;10(1):55.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"1365_CR17","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a\u00a0comprehensive cytokine profiling study. J\u00a0Clin Oncol. 2011;29(10):1356\u201363.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1365_CR18","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","volume":"126","author":"M Deininger","year":"2015","unstructured":"Deininger M, Radich J, Burn TC, et al. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood. 2015;126(13):1551\u20134.","journal-title":"Blood"},{"key":"1365_CR19","unstructured":"Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Changes in bone marrow morphology in patients with myelofibrosis treated for up to 5 years with either ruxolitinib or best available therapy. 19th European Hematology Association (EHA) annual meeting 2014 Abstract #P405"},{"issue":"20","key":"1365_CR20","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, et\u00a0al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"4","key":"1365_CR21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, et\u00a0al. DIPSS plus: a\u00a0refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J\u00a0Clin Oncol. 2011;29(4):392\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1365_CR22","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/leu.2016.283","volume":"31","author":"M Marchetti","year":"2017","unstructured":"Marchetti M, Barosi G, Cervantes F, et al. Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. Leukemia. 2017;31(4):882\u20138.","journal-title":"Leukemia"},{"key":"1365_CR23","unstructured":"Polverelli N, Benevolo G, Palumbo GA, et al. Predictors for response to ruxolitinib in real-life: an observational independent study on 266 patients with myelofibrosis. 21st European Hematology Association (EHA) annual meeting 2016 Abstr. #P672"},{"issue":"9","key":"1365_CR24","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","volume":"101","author":"HK Al-Ali","year":"2016","unstructured":"Al-Ali HK, Griesshammer M, le Coutre P, et al. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a\u00a0snapshot of 1144 patients in the JUMP trial. Haematologica. 2016;101(9):1065\u201373.","journal-title":"Haematologica"},{"key":"1365_CR25","unstructured":"Passamonti F, Gupta V, Martino B, et al. Comparing the safety and efficacy of ruxolitinib (RUX) in patients (PTS) with DIPSS low\/intermediate-1-, intermediate-2-, and high-risk myelofibrosis (MF) in JUMP, a phase 3b, expanded-access study. 22nd European Hematology Association (EHA) annual meeting 2017 Abstract #E1333"},{"issue":"1","key":"1365_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.13379","volume":"170","author":"AJ Mead","year":"2015","unstructured":"Mead AJ, Milojkovic D, Knapper S, et al. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. Br J Haematol. 2015;170(1):29\u201339.","journal-title":"Br J Haematol"},{"issue":"10","key":"1365_CR27","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1080\/10428194.2016.1195501","volume":"57","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Talpaz M, Mead AJ. Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a\u00a0summary of recent evidence. Leuk Lymphoma. 2016;57(10):2259\u201367.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1365_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/cpdd.77","volume":"3","author":"X Chen","year":"2014","unstructured":"Chen X, Shi JG, Emm T, et\u00a0al. Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients. Clin Pharmacol Drug Dev. 2014;3(1):34\u201342.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1365_CR29","unstructured":"European Medicines Agency. Jakavi (ruxolitinib): Summary of product characteristics, 2017. http:\/\/ec.europa.eu ."},{"issue":"9","key":"1365_CR30","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","volume":"100","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100(9):1139\u201345.","journal-title":"Haematologica"},{"issue":"4","key":"1365_CR31","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s12185-016-2050-y","volume":"104","author":"MK Song","year":"2016","unstructured":"Song MK, Chung JS, Lim SN, et\u00a0al. Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis. Int J Hematol. 2016;104(4):476\u201384.","journal-title":"Int J Hematol"},{"issue":"33","key":"1365_CR32","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL, et\u00a0al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J\u00a0Clin Oncol. 2012;30(33):4098\u2013103.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1365_CR33","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3324\/haematol.2010.026708","volume":"95","author":"PA Beer","year":"2010","unstructured":"Beer PA, Campbell PJ, Green AR. Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase. Haematologica. 2010;95(11):1960\u20133.","journal-title":"Haematologica"},{"issue":"3","key":"1365_CR34","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/ajh.23637","volume":"89","author":"H Gisslinger","year":"2014","unstructured":"Gisslinger H, Schalling M, Gisslinger B, et\u00a0al. Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis. Am J Hematol. 2014;89(3):344\u20136.","journal-title":"Am J Hematol"},{"key":"1365_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/OTT.S53348","volume":"7","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Gotlib J, Gupta V, et\u00a0al. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther. 2013;7:13\u201321.","journal-title":"Onco Targets Ther"},{"issue":"12","key":"1365_CR36","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","volume":"98","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a\u00a0median 2\u2011year follow-up of COMFORT-I. Haematologica. 2013;98(12):1865\u201371.","journal-title":"Haematologica"},{"issue":"1","key":"1365_CR37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1756-8722-6-81","volume":"6","author":"M Talpaz","year":"2013","unstructured":"Talpaz M, Paquette R, Afrin L, et\u00a0al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J\u00a0Hematol Oncol. 2013;6(1):81.","journal-title":"J Hematol Oncol"},{"issue":"23","key":"1365_CR38","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.V126.23.2817.2817","volume":"126","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Gisslinger H, Harrison CN, et al. EXPAND: a phase 1b, open-label, dose-finding study of Ruxolitinib in patients with Myelofibrosis (MF) and low platelet counts (50 \u00d7 109\/L to 99 \u00d7 109\/L) at baseline. Blood. 2015;126(23):2817.","journal-title":"Blood"},{"issue":"12","key":"1365_CR39","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","volume":"86","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011;86(12):1188\u201391.","journal-title":"Mayo Clin Proc"},{"issue":"15","key":"1365_CR40","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMc1109555","volume":"365","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N\u00a0Engl J Med. 2011;365(15):1455\u20137.","journal-title":"N Engl J Med"},{"key":"1365_CR41","unstructured":"Cris\u00e1 E, Cilloni D, Elli EM, et al. Erythropoiesis stimulating agents can improve anemia in patients with myelofibrosis treated with ruxolitinib. 22nd European Hematology Association (EHA) annual meeting 2017 Abstract #E1332"},{"issue":"7","key":"1365_CR42","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1056\/NEJMc1302895","volume":"369","author":"RA Goldberg","year":"2013","unstructured":"Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N\u00a0Engl J Med. 2013;369(7):681\u20133.","journal-title":"N Engl J Med"},{"issue":"1","key":"1365_CR43","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/leu.2013.235","volume":"28","author":"G Caocci","year":"2014","unstructured":"Caocci G, Murgia F, Podda L, et\u00a0al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a\u00a0patient with myelofibrosis. Leukemia. 2014;28(1):225\u20137.","journal-title":"Leukemia"},{"key":"1365_CR44","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/1756-0500-5-552","volume":"5","author":"C Colomba","year":"2012","unstructured":"Colomba C, Rubino R, Siracusa L, et\u00a0al. Disseminated tuberculosis in a\u00a0patient treated with a\u00a0JAK2 selective inhibitor: a\u00a0case report. BMC Res Notes. 2012;5:552.","journal-title":"BMC Res Notes"},{"issue":"17","key":"1365_CR45","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1056\/NEJMc1502524","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N\u00a0Engl J Med. 2015;372(17):1670\u20131.","journal-title":"N Engl J Med"},{"key":"1365_CR46","unstructured":"Porpaczy E. JAK1\/2 inhibitor therapy-associated lymphomas in myelofibrosis arising from a\u00a0preexisting B\u2011cell clone. Blood. 2018. in press."},{"issue":"4","key":"1365_CR47","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.clml.2014.12.008","volume":"15","author":"RA Mesa","year":"2015","unstructured":"Mesa RA, Verstovsek S, Gupta V, et al. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. Clin Lymphoma Myeloma Leuk. 2015;15(4):214\u2013221.e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1365_CR48","unstructured":"Russell J, Sparksman D, Dicu A, et al. Ruxolitinib in myelofibrosis: a multicentre experience from the east of England. 22nd European Hematology Association (EHA) annual meeting 2017 Abstract #PB2057"},{"issue":"1","key":"1365_CR49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ccell.2017.11.009","volume":"33","author":"M Kleppe","year":"2018","unstructured":"Kleppe M, Koche R, Zou L, et\u00a0al. Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms. Cancer Cell. 2018;33(1):29\u201343e7.","journal-title":"Cancer Cell"},{"issue":"2","key":"1365_CR50","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/MOH.0000000000000320","volume":"24","author":"R Assi","year":"2017","unstructured":"Assi R, Verstovsek S, Daver N. \u2018JAK-ing\u2019 up the treatment of primary myelofibrosis: building better combination strategies. Curr Opin Hematol. 2017;24(2):115\u201324.","journal-title":"Curr Opin Hematol"},{"issue":"18","key":"1365_CR51","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1080\/14656566.2016.1252333","volume":"17","author":"P Bose","year":"2016","unstructured":"Bose P, Verstovsek S. Myelofibrosis: an update on drug therapy in 2016. Expert Opin Pharmacother. 2016;17(18):2375\u201389.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"1365_CR52","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00277-017-2938-5","volume":"96","author":"C Cerchione","year":"2017","unstructured":"Cerchione C, Peluso I, Nappi D, et\u00a0al. Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a\u00a0patient with primary myelofibrosis. Ann Hematol. 2017;96(4):697\u20139.","journal-title":"Ann Hematol"},{"issue":"2","key":"1365_CR53","first-page":"73","volume":"3","author":"ME Bjorn","year":"2014","unstructured":"Bjorn ME, de Stricker K, Kjaer L, Ellemann K, Hasselbalch HC. Combination therapy with interferon and JAK1-2 inhibitor is feasible: proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera. Leuk Res Rep. 2014;3(2):73\u20135.","journal-title":"Leuk Res Rep"},{"key":"1365_CR54","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/102476","author":"HC Hasselbalch","year":"2015","unstructured":"Hasselbalch HC, Bjorn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm. 2015; https:\/\/doi.org\/10.1155\/2015\/102476 .","journal-title":"Mediators Inflamm."},{"issue":"5","key":"1365_CR55","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/leu.2016.12","volume":"30","author":"S Koschmieder","year":"2016","unstructured":"Koschmieder S, Mughal TI, Hasselbalch HC, et\u00a0al. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia. 2016;30(5):1018\u201324.","journal-title":"Leukemia"},{"issue":"3","key":"1365_CR56","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.currproblcancer.2013.06.001","volume":"37","author":"W Jeong","year":"2013","unstructured":"Jeong W, Doroshow JH, Kummar S. United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies. Curr Probl Cancer. 2013;37(3):110\u201344.","journal-title":"Curr Probl Cancer"}],"updated-by":[{"DOI":"10.1007\/s00508-018-1428-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T00:00:00Z","timestamp":1544572800000}}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-018-1365-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-018-1365-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-018-1365-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T02:10:09Z","timestamp":1571623809000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-018-1365-5"}},"subtitle":["Consensus on therapy management"],"short-title":[],"issued":{"date-parts":[[2018,7,24]]},"references-count":56,"journal-issue":{"issue":"17-18","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["1365"],"URL":"https:\/\/doi.org\/10.1007\/s00508-018-1365-5","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,24]]},"assertion":[{"value":"17 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction to:Wien Klin Wochenschr 2018\n                      \n                      The original version of this article unfortunately contained a\u00a0mistake. Table Nr.\u00a01 was inconsistent. The corrected version of Table\u00a01 is given below. We apologize for any inconveniences this may have \u2026","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.-T.\u00a0Krauth, S.\u00a0Burgstaller, V.\u00a0Buxhofer-Ausch, G.\u00a0Gastl, K.\u00a0Geissler, F.\u00a0Keil, P.\u00a0Krippl, T.\u00a0Melchardt, A.\u00a0Petzer, H.\u00a0Rumpold, T.\u00a0Sliwa, S.\u00a0W\u00f6hrer, A.\u00a0W\u00f6lfler and H.\u00a0Gisslinger have no conflicts of interest to declare except remuneration for consultant and\/or advisory role from Novartis Pharma GmbH.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}